Other Cancer News
Top Stories
Study Supports Possible Use Of Leukine As A Potential Adjuvant Therapy For High-risk Melanoma Patients
POSTED: June 13, 2008Results from an adjuvant trial in high-risk melanoma patients demonstrated that a majority of patients treated with Leukine(R) (sargramostim) achieved disease-free and/or overall survival. These findings, which indicate Leukine's potential in this cancer setting, were released at the 44th annual meeting of the American Society of Clinical Oncology (ASCO...
Dark Skin Doesn't Deflect Sun Risks
POSTED: June 13, 2008WALNUT CREEK, Calif. -- Like most children, Shoko Kiyono of El Cerrito, Calif., spent countless hours of her youth playing under the sun. Kiyono, who grew up in Japan, never wore sunscreen. No one spoke about the sun's harmful rays, though she was encouraged to wear a hat to keep her face "light and pretty," she says. The hat only did so much. Contra...
Poniard Announces Positive Efficacy And Safety Data From Phase 1 Trial Of Picoplatin In Multiple Tumor Types Including Ovarian Cancer
POSTED: June 13, 2008Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on oncology, announced safety and efficacy results from a previously unpublished Phase 1 clinical trial of picoplatin and liposomal doxorubicin in patients with advanced solid tumors, including ovarian cancer. Results demonstrated signals of clinical activity and acceptable toxicity with...
Epigenomics Successfully Completes Clinical Study In Lung Cancer Diagnosis
POSTED: June 10, 2008BERLIN and SEATTLE -- Epigenomics AG, a molecular diagnostics company focusing on the development and commercialization of products for cancer based on DNA methylation, today announced that it successfully completed a clinical study in its lung cancer program. The study was run in close collaboration with Prof. Dr. Christian Witt and Dr. Bernd S...
Doctor Presents Groundbreaking Study On Liver Cancer
POSTED: June 10, 2008A clinical trial of a liver cancer treatment at the Goshen Health System Center for Cancer Care, the only one of its kind in the United States, is yielding promising results, says Dr. Seza Gulec, who oversees the study. Gulec, who heads the endocrine surgery, hepatic oncology, molecular imaging and position emission tomography programs at the...
Researchers Blame HPV For Rise In Throat Cancer
POSTED: June 10, 2008CHICAGO -- For five grueling months in 2006 and 2007, Carol Kanga suffered through treatment for a life-threatening case of throat cancer linked to an unlikely source: a sexually transmitted viral infection. Unable to swallow food or water during chemotherapy and radiation treatment, Kanga was fed through a stomach tube. Her one respite came on Thank...
Genetic Mutation Associated With Increased Risk Of Lung Cancer
POSTED: June 10, 2008Carriers of a common genetic disorder previously linked to lung disease may have a 70-percent to 100-percent increased risk of lung cancer, according to a report in the May 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. The disorder, alpha1-antitrypsin deficiency (a1ATD), is one of the most common genetic conditions aff...
Stars To Appear In Public Service Announcements Benefiting The Ovarian Cancer Research Foundation
POSTED: June 10, 2008WEST CHESTER, Pa. -- Kelly Ripa and Molly Sims are packing a one-two punch in the fight against ovarian cancer as the stars of the new public service announcements to promote QVC(R) Presents Super Saturday Live to benefit The Ovarian Cancer Research Fund (OCRF). Ripa and Sims are scheduled to appear in both the print and television public ser...
BiPar Sciences Expands Clinical Development Of BSI-201 With Phase 2 Trial In Uterine Cancer
POSTED: June 10, 2008BiPar Sciences, Inc. announced it has expanded its clinical trials program through the initiation of an additional Phase 2 study of its lead product candidate BSI-201. The trial will assess BSI-201, the first ADP-ribose polymerase (PARP) inhibitor in the company's DNA repair portfolio, for the treatment of uterine carcinosarcoma or malignant mixed mulle...
Neoprobe Commences Lymphoseek Phase 3 Trial-multicenter Clinical Study Of Patients With Breast Cancer Or Melanoma Initiated
POSTED: June 10, 2008DUBLIN, Ohio -- Neoprobe Corporation, a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that a multicenter Phase 3 study of Lymphoseek(R) has been initiated in patients with either breast cancer or melanoma. The Phase 3 study will evaluate the efficacy of Lymphoseek to identify ly...
